Pharmacists' role in facilitating evidence-based prescribing for unlabeled use of medications

American Journal of Health-System Pharmacy

Volumn 66, Issue 19, 2009, Pages 1735-1739

  Macaulay, Tracy E ^a,b   Cook, Aaron M ^a,b   Fink III, Joseph L ^c   Rapp, Robert P ^c   Vincent III, William R ^d,e  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

^c Department of Pharmacotherapy and Translational Research   (United States)

^d LONG ISLAND UNIVERSITY   (United States)

^e BROOKLYN HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG APPROVAL; DRUG INFORMATION; DRUG LABELING; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HEALTH EDUCATION; HUMAN; MEDICAL LITERATURE; MEDICAL PRACTICE; NOTE; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

DRUG INDUSTRY; DRUG INFORMATION SERVICES; DRUG LABELING; EVIDENCE-BASED MEDICINE; GUIDELINES AS TOPIC; HEALTH PERSONNEL; HUMANS; MARKETING OF HEALTH SERVICES; PHARMACISTS; PRESCRIPTION DRUGS; PROFESSIONAL ROLE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70349757051     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080352     Document Type: Note

References (37)

1. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006; 166:1021-1026
2. Conroy S, Choonara I, Impicciatore P et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ. 2000; 320:79-82. (Pubitemid 30173044)
3. American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol. 2006; 24:3206-3208
4. Dzik WH. Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII. J Intensive Care Med. 2006; 21:54-59
5. U.S. Food and Drug Administration. Guidance for industry: good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices. www.fda.gov/RegulatoryInformation/ Guidances/ucm125126.htm (accessed 2009 Jun 29).
6. Mitka M. Critics say FDA's off-label guidance allows marketing disguised as science. JAMA. 2008; 299:1759-1761 (Pubitemid 351549988)
7. Stafford RS. Regulating off-label drug use - rethinking the role of the FDA. N Engl J Med. 2008; 358:1427-1429
8. Demonaco HJ, Ali A, Hippel E. The major role of clinicians in the discovery of off-label drug therapies. Pharmacotherapy. 2006; 26:323-32. (Pubitemid 43334671)
9. U.S. Const., Amendment 10.
10. U.S. Const. Art. I, §8, cl. 3
11. Wing KR, Gilbert B. The law and the public's health. 7th ed. Chicago: Health Administration; 2006.
12. Sterling Drug Inc. v. Cornish, 370 F.2d 82, 85 (8th Cir. 1966).
13. Springhill Hospitals Inc. v. Larrimore. www.alabamaappellatewatch.com/ springhill.pdf (accessed 2009 Jun 29).
14. Brushwood DB, Nanni KR. Hospital liability for accuracy of pharmacist consultations. Am J Health-Syst Pharm. 2009; 66:680-3.
15. Wyeth v. Levine, No.06-1249, 555 U.S. - (2009).
16. Acetadote (acetylcysteine injection) package insert. Nashville: Cumberland Pharmaceuticals Inc.; 2006.
17. Merrem (meropenem) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2008.
18. Selected item from the FDA Drug Bulletin. Use of drugs for unapproved indications: legal responsibility. www.pubmedcentral.nih.gov/picrender.fcgi? artid=1518763&blobtype=pdf (accessed 2009 Jun 29).
19. Thornton RG. The learned intermediary doctrine and its effects on prescribing physicians. Proc Bayl Univ Med Cent. 2003; 16:359-361
20. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §360aaa (1999).
21. Bradford WD, Kleit AN, Nietert PJ et al. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme A reductase inhibitors on attainment of LDL-C goals. Clin Ther. 2006; 28:2105-2118
22. Relman AS. Separating continuing medical education from pharmaceutical marketing. JAMA. 2001; 285:2009-2012
23. Pharmaceutical Research and Manufacturers of America. Code on interactions with healthcare professionals. www.phrma.org/code-on-interactions- with-healthcare-professionals (accessed 2008 Sep 1).
24. Hatton RC, Chavez ML, Jackson E et al. Pharmacists and industry: guidelines for ethical interactions. Pharmacotherapy. 2008; 28:410-420 (Pubitemid 351328914)
25. Department of Health and Human Services. Administration proposes additional funding for FDA to improve food and medical product safety. www.fda.gov/bbs/topics/NEWS/2008/NEW01849.html (accessed 2009 Mar 20).
26. Mitka M. Academic detailing bill. JAMA. 2008; 300:1290. News.
27. Countering the drug salesmen. www.nytimes.com/2008/03/20/opinion/20thru2. html (accessed 2009 Jun 29).
28. Independent Drug Education and Outreach Act, S.3396, H.R. 6752.
29. Lavine G. Pharmacists provide academic detailing to South Carolina health care providers. Am J Health-Syst Pharm. 2008; 65:2312-2314 News.
30. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. BMJ. 2003; 326:1189-1192
31. Steinbrook R. Financial support of continuing medical education. JAMA. 2008; 299:1060-1062 (Pubitemid 351347064)
32. Accreditation Council for Pharmacy Education. Accreditation standards for continuing pharmacy education. www.acpe-accredit.org/standards/default.asp (accessed 2009 Mar 20).
33. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of de-compensated congestive heart failure: a randomized controlled trial. JAMA. 2002; 287:1531-1540 [Erratum, JAMA. 2002; 288:577.]
34. Kesselheim AS, Fischer MA, Avorn J. The rise and fall of Natrecor for congestive heart failure: implications for drug policy. Health Aff. 2006; 25:1095-1102 (Pubitemid 44188246)
35. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacotherapy. 2004; 38:579-585 (Pubitemid 38352217)
36. Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358:1431-1443
37. Askew JP. Journal club 101 for the new practitioner: evaluation of a clinical trial. Am J Health-Syst Pharm. 2004; 61:1885-1887